MedTrace Logo

Effect of Carnitine on Uremic Cardiomyopathy

NCT02322697 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-12-25

No results posted yet for this study

Summary

Patients on chronic hemodialysis without obstructive coronary artery disease identified by coronary angiography were randomly divided into the two groups: carnitine group and control group. SPECT using FFA analogue, BMIPP, was performed before and one year after intravenous administration of L-carnitine (1000 mg on every dialysis session). Control group received the examination of BMIPP SPECT at the same time of the carnitine group. The effects of chronic intravenous administration of L-carnitine on myocardial fatty acid metabolism were investigated among this population.

Conditions

  • Disorder of Fatty Acid Metabolism

Interventions

DRUG

Intravenous administration of L-carnitine

Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients

Sponsors & Collaborators

  • Toujinkai Hospital

    lead OTHER

Principal Investigators

  • Masato Nishimura, MD · Toujinkai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-10-31
Completion
2014-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322697 on ClinicalTrials.gov